Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the 10 Oversold Small Cap Stocks to Buy Now.
At the close on April 24, consensus sentiment around the stock was strongly bullish. It received Buy ratings from all 12 analysts who provided coverage. Additionally, it offers nearly 150% upside potential based on a 1-year average price target of $64.45, making it one of the most attractive small-cap options.
Pressmaster/Shutterstock.com
The bullish views are also supported by the company’s latest test results. On March 25, Maze Therapeutics Inc. (NASDAQ:MAZE) revealed encouraging results from the Phase 2 HORIZON trial of MZE829, an oral drug that inhibits APOL1, in the treatment of a variety of APOL1-induced kidney diseases. 12 weeks of drug administration caused a 35.6% reduction in the mean value of the albumin/creatinine ratio in patients with extensive AMKD, where 50% of patients had a reduction greater than 30%.
Patients diagnosed with FSGS saw a reduction in the mean value of 61.8%, while those with non-diabetic AMKD saw a reduction of 48.6%. There were no serious side effects. Maze intends to make the drug a cornerstone program. Harold Bernstein, president of R&D and chief medical officer, said the results demonstrate an encouraging proof of concept for precision medicine to address the cause of AMKD.
Maze Therapeutics Inc. (NASDAQ:MAZE) is a developer of small molecule precision medicines for the treatment of metabolic and kidney diseases. The company’s core programs include MZE829, APOL1 and MZE782. In addition, he is also involved in the development of MZE001. The company has agreements with various organizations for the licensing and marketing of its products.
While we recognize MAZE’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 33 stocks that should double in 3 years and 15 stocks that will make you rich in 10 years.
Disclosure: None. Follow Insider Monkey on Google News.